Their efficacy and safety has yet to be proven in Phase III RCTs. curative treatment is being evaluated in clinical Fevipiprant studies. Future research should lead to a molecular classification of the disease and a more personalized treatment approach. Keywords:hepatocellular carcinoma, sorafenib == Introduction to treatment management of hepatocellular carcinoma update on use of biologics and emerging treatment options == Hepatocellular carcinoma (HCC) is a major health problem. It is the sixth most common cancer worldwide and the third cause of cancer-related death.1In 2002 at least 600,000 new cases were registered and its incidence and prevalence in US and Western Europe have been increasing during the past decade. In 80% of cases HCC affects cirrhotic livers and it is now considered the first complication to occur and the major cause of liver-related death.2Principal risk factors Rabbit Polyclonal to P2RY8 for developing cirrhosis and then HCC are chronic liver diseases and in particular chronic B and C hepatitis/cirrhosis, alcoholic liver disease and nonalcoholic steatohepatitis-related cirrhosis.35Guidelines for HCC management Fevipiprant recommend mortality risk estimates as a decision-making support.3Unfortunately, the ability of all the available prognostic scores to predict mortality is far from perfect and none Fevipiprant of these systems provide sufficient confidence for the prediction of the outcome in the individual patient with HCC.3,68 In the absence of an optimum prognostic model, treatment algorithms for patients with HCC in Europe and North America have been prepared on the basis of the Barcelona Clinic Liver Cancer (BCLC) classification.3,9,10 The BCLC staging classification for HCC classifies patients as having stages of disease from 0 to D (Figure 1). == Figure 1. == The Barcelona Clinic Liver Cancer staging system and treatment allocation. Copyright 2010, American Association for the study of Liver Diseases. Adapted with permission from Bruix J, Sherman M. Management of hepatocellular carcinoma: an update.Hepatology. 2010;135. Available from:http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20practice%20Guidelines/Hccupdate2010.pdf. Accessed on Nov 3, 2010. Abbreviations:CLT, cadaveric liver transplantation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; PEI, percutaneous ethanol injection; RF, radiofrequency. Stage 0 is very early disease, which is defined as a solitary liver cancer that measures 2 cm without tumor invasion into surrounding tissues. Stage A is early disease, classified as patients who exhibit preserved liver function with a solitary HCC <5 cm in size, or up to 3 tumors each of which is 3 cm in size. Patients with stage 0 or stage A disease can be effectively treated with curative therapies, such as surgical resection, liver transplantation, or by percutaneous ablation methods, including percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA). With these treatments it is possible to obtain complete responses with potential long-term cure, as reflected by a 5-year survival better than 50% to 70%. The BCLC intermediate stage (stage B) consists of asymptomatic patients with well-preserved liver function, and multinodular or large tumor extension, without macrovascular invasion or extrahepatic spread (ES). Patients with stage B (intermediate) disease treated with transarterial embolization (TAE) or transarterial chemoembolization (TACE) have demonstrated a significant increase in survival compared with best supportive care (median survival, 20 months vs 16 months). Patients with mild related symptoms and/or macrovascular invasion or ES are classified as advanced stage (BCLC stage C). Previously, no standard systemic therapy existed for the treatment of patients at this stage; however, two randomized controlled trials (RCTs) have now shown that sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor (VEGFR), improves the overall survival of patients with stage C disease. Sorafenib is, therefore, now considered to be the standard treatment for advanced HCC.11,12Patients with cancer symptoms, related to progressed liver failure, tumor growth with vascular involvement, ES, or physical impairment (performance status >2) are classified as stage D (end stage) disease; they do not benefit from antitumor treatments and should receive only the best available supportive care. It should be noted that not all patients defined by each stage of BCLC are ultimately candidates for the suggested treatment modality. For instance, TACE can be performed at an early stage in patients for whom RFA or PEI cannot be performed because of tumor location (proximity to a gallbladder, biliary tree, or blood vessel), or because of failed prior curative treatments or medical comorbidities. TACE is also the first-line therapy for downstaging tumors that exceed the criteria for transplantation or in patients awaiting orthotopic liver organ transplantation (OLT). Furthermore, even if suggestions for the administration of HCC offer indications for the usage of several remedies as monotherapies, in scientific practice a multimodal strategy that combines several techniques can be used, either as first-line therapy or being a recovery (second-line) approach following the failure of the monotherapy (Desk 1).13,14 == Desk 1. == The suggested purpose of.